NCT05553145Completed
The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary Care
Source: ClinicalTrials.gov · Last updated 10 Jan 2025
Brief summary (registry, in English)
The purpose of this study is to assess the levels of autoimmune markers of diabetes in those with a type 2 diabetes diagnosis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 21 Sept 2022
- Start date
- 1 Sept 2022
- Primary completion date
- 31 May 2023
- Lead sponsor
- The Cleveland Clinic
- Diseases
- Type 2 diabetes
- NCT number
- NCT05553145
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 1 Sept 2022 to the primary completion date, 31 May 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with a diagnosis of T1D or LADA in their problem list
- Patients with an encounter diagnosis for T1D or LADA
- Mental incapacity or language barrier (non-English speaking)
Who the study is looking for
- Language: English
- Age: ≥ 18
- Type 2 diabetes
- Ability to provide informed consent before any trial-related activities. Trial-related activities are any procedure that would not have been performed during normal management of the subject.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Twinsburg Family Health & Surgery Center Coordinator of this site? Confirm its status | Twinsburg | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.